Omnicell (NASDAQ:OMCL) Downgraded to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research note issued to investors on Monday morning.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Company dropped their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Benchmark reissued a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Finally, JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $51.00.

Omnicell Stock Up 3.5 %

OMCL stock opened at $35.14 on Monday. The company’s 50-day moving average price is $39.63 and its 200 day moving average price is $42.83. The company has a market cap of $1.64 billion, a P/E ratio of 130.15, a P/E/G ratio of 7.53 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.75.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, research analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

Institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its position in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after acquiring an additional 273 shares during the period. Summit Investment Advisors Inc. grew its holdings in shares of Omnicell by 6.9% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock worth $213,000 after purchasing an additional 307 shares during the period. Van ECK Associates Corp grew its holdings in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares during the period. First Horizon Advisors Inc. increased its position in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares in the last quarter. Finally, Redmond Asset Management LLC raised its holdings in Omnicell by 0.3% in the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock valued at $5,396,000 after buying an additional 371 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.